Lomitapide

Lomitapide

SCHEMBL2731380

CS(=O)(=O)O.O=C(NC1CCN(CCCCC2(C(=O)NCC(F)(F)F)c3ccccc3-c3ccccc32)CC1)c1ccccc1-c1ccc(C(F)(F)F)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

MTTPP4HB

The experimentally established mechanism targets of Lomitapide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MTTP known ✓ P55157 15/20 1.00
CHRM2 P08172 1/20 0.93
ADRA2A P08913 1/20 0.93
ADORA3 P0DMS8 1/20 0.93
CHRM1 P11229 1/20 0.93
DRD1 P21728 1/20 0.93
TBXA2R P21731 1/20 0.93
PTGS1 P23219 1/20 0.93
SLC6A2 P23975 1/20 0.93
ADRA1A P35348 1/20 0.93
OPRM1 P35372 1/20 0.93
DRD3 P35462 1/20 0.93
SLC6A3 Q01959 1/20 0.93
KCNH2 Q12809 1/20 0.93
MTR Q99707 1/20 0.93

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lomitapide SCHEMBL29367678 1.00 MTTP (1.00) MTTPCHRM2ADRA2AADORA3CHRM1
Lomitapide SCHEMBL304604 0.96 MTTP (1.00) MTTPCHRM2ADRA2AADORA3CHRM1
Lomitapide SCHEMBL29355521 0.96 MTTP (1.00) MTTPCHRM2ADRA2AADORA3CHRM1
SCHEMBL16519940 0.92 MTTP (0.88) MTTPCHRM2ADRA2AADORA3CHRM1
SCHEMBL17460357 0.91 MTTP (0.83) MTTPCHRM2ADRA2AADORA3CHRM1
SCHEMBL19500371 0.90 MTTP (0.85) MTTPCHRM2ADRA2AADORA3CHRM1
SCHEMBL12588085 0.90 MTTP (0.85) MTTPCHRM2ADRA2AADORA3CHRM1
SCHEMBL8901728 0.90 MTTP (0.85) MTTPCHRM2ADRA2AADORA3CHRM1
SCHEMBL19509698 0.90 MTTP (0.88) MTTPCHRM2ADRA2AADORA3CHRM1
SCHEMBL6600443 0.89 MTTP (0.86) MTTPCHRM2ADRA2AADORA3CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017098522-A1 CRYSTALLINE POLYMORPH OF N-(2,2,2-TRIFLUOROETHYL-9-[4-[R4-R[[[I4'- (TRIFLUOROMETHYL) [ 1,1 ' -BIPHENYL] -2-YL] CARBONYL] AMINO] -1 -PIPERIDINYL] BUTYL] -9H- FLUORENE-9-CARBOXAMIDE METHANESULFONATE AND PROCESS FOR PREPARATION THEREOF MSN LABORATORIES PRIVATE LIMITED (IN) 2017-06-15 WO claimed
WO-2017098522-A1 CRYSTALLINE POLYMORPH OF N-(2,2,2-TRIFLUOROETHYL-9-[4-[R4-R[[[I4'- (TRIFLUOROMETHYL) [ 1,1 ' -BIPHENYL] -2-YL] CARBONYL] AMINO] -1 -PIPERIDINYL] BUTYL] -9H- FLUORENE-9-CARBOXAMIDE METHANESULFONATE AND PROCESS FOR PREPARATION THEREOF MSN LABORATORIES PRIVATE LIMITED (IN) 2017-06-15 WO disclosed
US-20160083345-A1 POLYMORPHIC FORMS OF LOMITAPIDE AND ITS SALTS AND PROCESSES FOR THEIR PREPARATION CADILA HEALTHCARE LIMITED (IN) 2016-03-24 US disclosed
US-9000175-B2 Bicyclic GPR119 modulators LUPIN LIMITED (IN) 2015-04-07 US disclosed
US-20130245000-A1 BICYCLIC GPR119 MODULATORS LUPIN LIMITED (IN) 2013-09-19 US disclosed
WO-2012025811-A1 INDOLYLPYRIMIDINES AS MODULATORS OF GPR119 LUPIN LIMITED (IN) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160083345-A1 POLYMORPHIC FORMS OF LOMITAPIDE AND ITS SALTS AND PROCESSES FOR THEIR PREPARATION LIPA, CETP, MTTP MTTP 3/4885CHRM2 1677/4885ADRA2A 125/4885
US-20130245000-A1 BICYCLIC GPR119 MODULATORS GPR119, GPR180, GPBAR1 MTTP 656/4885CHRM2 291/4885ADRA2A 77/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.